Rhinocort (budesonide) is an anti-inflammatory glucocorticosteroid for the once-daily treatment of non-infectious rhinitis, and for treatment and prevention of nasal polyposis. Non-infectious rhinitis includes seasonal allergic rhinitis (hay fever), perennial allergic rhinitis (e.g. house dust mite allergy), and perennial non-allergic rhinitis.
The following nasal formulations of Rhinocort are available: RhinocortAqua (a water-based suspension in a pump spray), RhinocortTurbuhaler (nasal inhalation powder), and Rhinocort pMDI (pressurised metered dose inhaler).
Did you know?
AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.
Links to country-specific websites can be found using the AstraZeneca websites list.
If you still have a question regarding our drug portfolio you can Contact us.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:04 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
